Variety of qualified patients: CDEC reviewed the uncertainty in the amount of patients with moderately critical to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical experts consulted by CADTH indicated that some individuals who're classified as possessing delicate or reasonable condition can have a critical bleeding phenotype, which https://hemgenix17260.blogdal.com/36476958/everything-about-hemgenix